Micro Emerging Active

Il titolo CORT sale grazie al trattamento antitumorale Lyforli

Punteggio
0,3
Velocità
▲ 0,0
Articoli
4
Fonti
2

Riepilogo

Un articolo appartiene a questa narrazione se discute le performance azionarie di Corcept Therapeutics relative al suo trattamento antitumorale Lyforli.

Articoli Correlati

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday

Nasdaq · Mar 25, 2026
Mixed

Fonti

Corcept Therapeutics Incorporated (CORT) Gains on FDA Approval, But Questions … Yahoo Finance
Why Corcept Therapeutics Zoomed Nearly 9% Higher This Week Nasdaq
Corcept Therapeutics (CORT) Climbs 19.7% as Lifyorli Gets FDA OK Yahoo Finance
Why Investors Strapped a Rocket to Corcept Therapeutics Stock on … Nasdaq

Cronologia

Ultimo aggiornamento Mar 25, 2026